Company Info

Cellectis

Drug Discovery & Development

Overview

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing—built on its flagship TALEN^® technology and pioneering electroporation system PulseAgile—Cellectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

2 Contributions1 / 1

Allogeneic CAR-T

FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients

Cellectis

PR-M04-19-NI-028Apr 09, 2019

Clinical Trials

FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Cellectis

PR-M11-17-NI-001Nov 07, 2017

1 / 1

0 Contributors1 / 0

No authors found

1 / 0